Alpha7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction plays an important role in schizophrenia. Positive allosteric modulators of α7 nAChR have emerged as a promising therapeutic approach to manage cognitive deficits that are inadequately treated in schizophrenic patients. The aim of the present study was to evaluate the ability of type I (CCMI) and type II (PNU120596) α7 nAChR positive allosteric modulators to counteract MK-801-induced cognitive and sensorimotor gating deficits. The activity of these compounds was compared with the action of the α7 nAChR agonist A582941. CCMI, PNU120596 and A582941 reversed the sensorimotor gating impairment evoked by MK-801 based on the prepulse inhibition of the startle response. Additionally, no MK-801-evoked working memory deficits were observed with α7 nAChR ligand pretreatment as assessed in a discrete paired-trial delayed alternation task. However, these compounds did not affect the rats’ attentional performances in the five-choice serial reaction time test. The α7 nAChR agents demonstrated a beneficial effect on sensorimotor gating and some aspects of cognition tested in a rat model of schizophrenia. Therefore, these results support the use of α7 nAChR positive allosteric modulators as a potential treatment strategy in schizophrenia.
AlexanderKSWuHQSchwarczR. (2012) Acute elevations of brain kynurenic acid impair cognitive flexibility: Normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl)220: 627–637.
2.
AmitaiNMarkouA (2009) Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl)202: 275–286.
3.
AndersonDJBunnelleWSurberB. (2008) [3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]hept ane], a novel high-affinity alpha7 neuronal nicotinic receptor agonist: Radioligand binding characterization to rat and human brain. J Pharmacol Exp Ther324: 179–187.
4.
ArendashGWSengstockGJSanbergPR. (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res674: 252–259.
5.
AultmanJMMoghaddamB (2001) Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl)153: 353–364.
6.
AzzopardiETypltMJenkinsB. (2013) Sensorimotor gating and spatial learning in alpha7-nicotinic receptor knockout mice. Genes Brain Behav12: 414–423.
7.
BakshiVPSwerdlowNRGeyerMA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther271: 787–794.
8.
BastTZhangWFeldonJ. (2000) Effects of MK801 and neuroleptics on prepulse inhibition: Re-examination in two strains of rats. Pharmacol Biochem Behav67: 647–658.
9.
BitnerRSBunnelleWHAndersonDJ. (2007) Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci27: 10578–10587.
10.
BlondelASangerDJMoserPC (2000) Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: Antagonist studies. Psychopharmacology (Berl)149: 293–305.
11.
BoessFGDe VryJErbC. (2007) The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther321: 716–725.
12.
BraffDLGrillonCGeyerMA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry J49: 206–215.
13.
BuccafuscoJJTerryAVJrDeckerMW. (2007) Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol74: 1202–1211.
14.
CallahanPMHutchingsEJKilleNJ. (2013) Positive allosteric modulator of alpha7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology67: 201–212.
15.
CallahanPMTerryAVJrTehimA (2014) Effects of the nicotinic alpha7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats. Psychopharmacology (Berl)231: 3695–3706.
16.
ChanWKWongPTSheuFS (2007) Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology52: 1641–1649.
17.
ChenWJFaraoneSV (2000) Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am J Med Genet97: 52–57.
18.
CornblattBAMalhotraAK (2001) Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet105: 11–15.
19.
DudchenkoPATalposJYoungJ. (2013) Animal models of working memory: A review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Neurosci Biobehav Rev37: 2111–2124.
20.
DunlopJLockTJowB. (2009) Old and new pharmacology: Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b’]di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther328: 766–776.
21.
EskildsenJRedrobeJPSamsAG. (2014) Discovery and optimization of Lu AF58801, a novel, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors: Attenuation of subchronic phencyclidine (PCP)-induced cognitive deficits in rats following oral administration. Bioorg Med Chem Lett24: 288–293.
22.
FijalKPopikPNikiforukA (2014) Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: Effects on prepulse inhibition in rats. Psychopharmacology (Berl)231: 269–281.
23.
FreedmanRHallMAdlerLE. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry38: 22–33.
24.
FreedmanROlincyABuchananRW. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry165: 1040–1047.
25.
GeyerMAKrebs-ThomsonKBraffDL. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl)156: 117–154.
26.
GottiCRigantiLVailatiS. (2006) Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des12: 407–428.
27.
GreenMFNuechterleinKHGoldJM. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry56: 301–307.
28.
GronlienJHHakerudMWeenH. (2007) Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol72: 715–724.
29.
GrottickAJHigginsGA (2000) Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res117: 197–208.
30.
GuanZZZhangXBlennowK. (1999) Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport10: 1779–1782.
31.
HahnBSharplesCGWonnacottS. (2003) Attentional effects of nicotinic agonists in rats. Neuropharmacology44: 1054–1067.
32.
HahnBShoaibMStolermanIP (2002) Nicotine-induced enhancement of attention in the five-choice serial reaction time task: The influence of task demands. Psychopharmacology (Berl)162: 129–137.
33.
HahnBShoaibMStolermanIP (2011) Selective nicotinic receptor antagonists: Effects on attention and nicotine-induced attentional enhancement. Psychopharmacology (Berl)217: 75–82.
34.
HaigGWangDOthmanAA. (2016) The alpha7 nicotinic agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia in nonsmokers: Results from a randomized controlled phase 2b study. Neuropsychopharmacology41: 2893–2902.
35.
HauserTAKucinskiAJordanKG. (2009) TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol78: 803–812.
36.
HigginsGAEnderlinMHamanM. (2003) The 5-HT2A receptor antagonist M100,907 attenuates motor and ‘impulsive-type’ behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl)170: 309–319.
37.
HoyleEGennRFFernandesC. (2006) Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl)189: 211–223.
38.
HurstRSHajosMRaggenbassM. (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: In vitro and in vivo characterization. J Neurosci25: 4396–4405.
39.
KellerJJKellerABBowersBJ. (2005) Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behav Brain Res162: 143–152.
40.
KjaerbyCBundgaardCFejginK. (2013) Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment. Neuropharmacology72: 157–168.
41.
KohlhaasKLBitnerRSGopalakrishnanM. (2012) Effects of alpha7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis. Psychopharmacology (Berl)220: 823–833.
42.
KohlhaasKLRobbHRoderwaldSM. (2016) 7 NNR allosteric modulation in behavioral models of cognition. Biochem Pharmacol82: 1023–1047.
43.
LeppikIEMarienauKGravesNM. (1988)MK-801 for epilepsy: A pilot study. Neurology38: 405.
44.
LevinEDBettegowdaCBlosserJ. (1999) AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol10: 675–680.
45.
LiebermanJADunbarGSegretiAC. (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology38: 968–975.
46.
LoosMStaalJSchoffelmeerAN. (2010) Inhibitory control and response latency differences between C57BL/6J and DBA/2J mice in a Go/No-Go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine. Behav Brain Res214: 216–224.
47.
McLeanSLIdrisNFGraysonB. (2012) PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol26: 1265–1270.
48.
MartinLFFreedmanR (2007) Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol78: 225–246.
49.
MeltzerHGawrylMWardS. (2011) EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. Neuropsychopharmacology36: 170–171.
50.
NgHJWhittemoreERTranMB. (2007) Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A104: 8059–8064.
51.
NikiforukAHolujMPotasiewiczA. (2015a) Effects of the selective 5-HT7 receptor antagonist SB-269970 on premature responding in the five-choice serial reaction time test in rats. Behav Brain Res289: 149–156.
52.
NikiforukAKosTHolujM. (2015b) Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropharmacology101: 389–400.
53.
NikiforukAKosTPotasiewiczA. (2015c) Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol25: 1300–1313.
54.
OlincyAHarrisJGJohnsonLL. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry63: 630–638.
55.
PandyaAAYakelJL (2013) Activation of the alpha7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT(1)a receptor antagonist. Neuropharmacology70: 35–42.
56.
PatelSStolermanIPAshersonP. (2006) Attentional performance of C57BL/6 and DBA/2 mice in the 5-choice serial reaction time task. Behav Brain Res170: 197–203.
57.
PaylorRNguyenMCrawleyJN. (1998) Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: A behavioral characterization of Acra7-deficient mice. Learn Mem5: 302–316.
58.
PotasiewiczAKosTRavazziniF. (2015) Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. Br J Pharmacol172: 5123–5135.
59.
RedrobeJPNielsenEOChristensenJK. (2009) Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. Eur J Pharmacol602: 58–65.
60.
RobbinsTW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl)163: 362–380.
61.
RujescuDBenderAKeckM. (2006) A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: Molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry59: 721–729.
62.
SmithJWGastambideFGilmourG. (2011) A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl)217: 255–269.
63.
TerryAVJrBuccafuscoJJSchadeRF. (2012) The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem Pharmacol83: 941–951.
64.
TerryAVJrRisbroughVBBuccafuscoJJ. (2002) Effects of (+/–)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther301: 284–292.
65.
ThomsenMSMikkelsenJD (2012) Type I and II positive allosteric modulators differentially modulate agonist-induced up-regulation of alpha7 nicotinic acetylcholine receptors. J Neurochem123: 73–83.
66.
ThomsenMSChristensenDZHansenHH. (2009) Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology56: 1001–1009.
67.
ThomsenMSEl-SayedMMikkelsenJD (2011) Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One6: e27014.
68.
TietjeKRAndersonDJBitnerRS. (2008) Preclinical characterization of A-582941: A novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther14: 65–82.
69.
TimmermannDBGronlienJHKohlhaasKL. (2007) An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther323: 294–307.
70.
UmbrichtDKeefeRSMurrayS. (2014) A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology39: 1568–1577.
71.
UteshevVV (2014) The therapeutic promise of positive allosteric modulation of nicotinic receptors. Eur J Pharmacol727: 181–185.
72.
YoungJWGeyerMA (2013) Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol86: 1122–1132.
73.
YoungJWCrawfordNKellyJS. (2007) Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol17: 145–155.
74.
YoungJWFinlaysonKSprattC. (2004) Nicotine improves sustained attention in mice: Evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology29: 891–900.
